Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (huCART19)

Condition(s)
Leukemia Lymphoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Biological treatment cell Biological
huCART19
Trial Summary

This is a pilot study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in patients with relapsed or refractory CD19+ leukemia and lymphoma that was previously treated with cell therapy. This study is targeting pediatric patients aged 1-24 years with CD19+ B cell malignancies with no available curative treatment options (such as autologous or allogeneic stem cell transplantation) who have a limited prognosis with currently available therapies and were previously treated with a B cell directed engineered cell therapy product.

Ages: 1 Year to 24 Years
Condition: Acute Lymphocytic Leukemia, Diffuse Large Cell Lymphoma
Status
Recruiting
Location(s)
Children's Hospital of Philadelphia (CHOP), Philadelphia, PA

Sponsor/Collaborator:
University of Pennsylvania
Contact
Mia Benson-Smith
267-426-0762